Zydus Cadila seeks DCGI emergency use approval for COVID vaccine ZyCoV-D

Published On 2021-07-01 07:30 GMT   |   Update On 2021-07-01 13:03 GMT
Advertisement

New Delhi: Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Drug Controller General of India (DCGI) for its COVID-19 vaccine ZyCoV-D.

The company said it has conducted the largest clinical trial for its COVID-19 vaccine in India so far in over 50 centres.

"The company has applied for EUA to the office of DCGI for ZyCoV-D - its Plasmid DNA vaccine against COVID-19," Zydus Cadila said in a statement.

Advertisement

Dr. Sharvil Patel, Managing Director, Cadila Healthcare, said the vaccine when approved will help not only adults but also adolescents in the 12 to 18 years age group.

Read also: Zydus Cadila gets USFDA nod for Pemetrexed for Injection

The company said it has also evaluated a two dose regimen for ZyCoV-D vaccine using a 3 mg dose per visit and the immunogenicity results had been found to be equivalent to the current three dose regimen.

This will further help in reducing the full course duration of vaccination while maintaining the high safety profile of the vaccine in the future, the company added.

Read also: Zydus Cadila COVID vaccine for children above 12 years expected by August: NTAGI chief




Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News